October 7, 2022

Tag: HEA

Market

Frost & Sullivan: Quantified-self Technologies Set to Transform Personal Health

— Innovations in sensor technology usher in an era of self-monitoring devices

MOUNTAIN VIEW, Calif., Aug. 26, 2014 /PRNewswire/ — The market for quantified-self technologies — apps that enable people to track and quantify aspects of their daily lives — is currently in the embryonic stage. However, explosive growth is expected in coming years as many companies successfully complete crowd sourcing activities for funding; an indication of the high interest the domain has generated. Communication, computing, data capture and feedback mechanisms will be key technology enablers for quantified-self.

The market for quantified-self technologies – apps that enable people to track and quantify aspects of their daily lives – is currently in the embryonic stage.

The market for quantified-self technologies – apps that enable people to track and quantify aspects of their daily lives – is currently in the embryonic stage.

New analysis from Frost & Sullivan, Sensor Technology Innovations Enabling Quantified-Self, finds that wearable technology has gained considerable traction especially in the health and wellness industry. Increasing momentum in the use of sensor-enabled wearable devices promises more design opportunities in the future.

For complimentary access to more information on this research, please visit: http://bit.ly/1BWbUxW

“The miniaturization trend has quickened development of improved and innovative wearable devices such as smart watches and smart glasses that monitor athletic performance and health,” said Technical Insights Senior Research Analyst Sumit Kumar Pal. “Quantified-self facilitates the tracking of diet, sleep, heart rate, activity, exercise and moods and allows individuals to gain better insights on physiological parameters that were never examined earlier.”

As healthcare is one of the main industries impacted by the quantified-self movement, acquiring accurate data and ensuring seamless interoperability are key challenges. In addition, data sharing among health services and pharmaceutical firms raises privacy concerns. Healthcare companies must ensure that data collected from clients is not shared without direct consent.

User perceived benefits will be another critical factor in the success of quantified-self products, along with affordability. To get the healthcare industry further involved in quantified-self, enhancing the connectivity of wearable devices with technology companies to support data exchange will also be crucial.

“Stakeholders are exploring other ecosystems with which quantified-self can be integrated,” added Pal. “Technological advancements in energy harvesting for mobile and wearable devices as well as in social networking dynamics will push the quantified-self industry into the next stage.”

Sensor Technology Innovations Enabling Quantified-Self, a part of the Technical Insights (http://www.technicalinsights.frost.com) subscription, offers technological and market insights on sensors enabling quantified-self. Along with a snapshot of the technology’s global footprint, the study discusses patent publishing trends, R&D focus, funding, and the impact of mega trends to provide a complete view of quantified-self technology. Detailed technology analysis and industry trends evaluated following extensive interviews with market participants.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on “the next big thing”

Register: Gain access to visionary innovation

Sensor Technology Innovations Enabling Quantified-Self
D547-TI

Contact:
Jennifer Carson
Corporate Communications – North America
P: +1-210-247-2450
F: +1-210-348-1003
E: jennifer.carson@frost.com

LinkedIn: Transform Health Group
Twitter: @Frost_Sullivan
Facebook: Frost & Sullivan

http://www.frost.com
http://www.technicalinsights.frost.com

Read More
Arts

Natural Beauty Announces 2014 Interim Results

Turnover Rose 22.1% to HK$248.5 Million

Contribution from Higher-margin Products Drove

Gross Margin Improvement

HONG KONG, Aug. 26, 2014 /PRNewswire/ — Natural Beauty Bio-Technology Limited (“Natural Beauty” or the “Group”; Stock Code: 00157), the leading professional skin-care, spa services and beauty training provider in China, announced today its interim results for the six months ended 30 June 2014.

For the six months ended 30 June 2014, turnover of the Group grew 22.1% to HK$248.5 million year-on-year (1H2013: HK$203.6 million), driven by an increase in product sales as a result of higher store productivity in Mainland China and Taiwan. Overall gross profit margin improved to 76.7%, as contribution from higher-margin products increased within the Group’s sales mix during the period (1H2013: 75.9%). Profit for the period amounted to HK$29.7 million for the six months ended 30 June 2014 (1H2013: HK$36.2 million). Earnings per share were 1.48 HK cents (1H2013: 1.81 HK cents). The Board recommended to distribute an interim dividend of 2.1 HK cents per share, equivalent to a dividend payout ratio of 141.5%.

Despite the economic growth slowdown in the Mainland China, turnover in the Mainland China market rose by 25.3% to HK$201.8 million for the six months ended 30 June 2014. The growth was driven by increase in sales of products, mainly due to the pilot-testing of “direct-own retail” management system to exercise better control over franchisees in order to drive higher store productivity. During the first half of 2014, gross margin on product sales was up 2.4 percentage points to 81.2%. Turnover for the Taiwan market also registered growth of 11.7% to HK$44.4 million, as the Group adopted door-by-door management via franchisee differentiation to utilize company resources efficiently. Gross margin on product sales expanded 3.5 percentage points to 82.4%. The gross margin improvement in both Mainland China and Taiwan was a result of higher sales contribution from higher-margin products such as NB-1, and lower promotion discounts during the period under review. On the other hand, sales in other regions, including Hong Kong, Macau and Malaysia, decreased 17.9% to HK$2.3 million for the six months ended 30 June 2014, accounting for an insignificant 0.9% of the Group’s turnover.  

The Group derives its income principally from its network of distribution channels, including spas and concessionary counters in department stores. As at 30 June 2014, there were 1,358 spas and 14 concessionary counters. A total of 11 new stores were opened and 72 stores were closed during the six months ended 30 June 2014.

During the period, average sales per store of the Group amounted to HK$179,000 (1H2013: HK$138,000), of which average sales per store in the Mainland China grew 32.6% to HK$183,000, while average sales per store in Taiwan increased by 20.6% to HK$164,000.

The Group puts significant emphasis on research and development which allows it to maintain its competitive edge by continuously improving the quality of its existing products and developing new products. The Group has been collaborating with overseas skin-care companies on technological development, drawing on the experience of its team of experts to continually create high-quality beauty and skin care products. During the six months ended 30 June 2014, nearly 191,395 sets/bottles of the Group’s flagship NB-1 family products were sold with turnover amounting to HK$101.3 million, accounting for more than one-third of the Group’s total product sales during the period. The Group has also collaborated with a leading researcher in the field of human genome and stem cell technology. The stem cell technology is patented in the United States to protect the uniqueness of the NB-1 products.

Ms. Karen Chang, Chief Executive Officer of the Group said, “In 2014, the beauty and personal care sector maintained better than GDP growth and we are pleased to have achieved a much higher growth than the industry. Our growth is mainly attributed to the improved channel quality by implementing ‘direct-own retail’ management methodology to drive much higher door productivity. In order to maintain the encouraging growth momentum, we will strengthen trainings provided to our franchisees to ensure their operational quality. We also rationalize our products lines by relaunching NB-1 Revital products to increase the penetration of home care. We will press on with our prudent growth strategy, and strive to strengthen our position as a leading skin care brand and spa operator in the Greater China Region, so as to generate better returns for our shareholders.”

– End –

About Natural Beauty Bio-Technology Limited

Natural Beauty is a leading beauty and spa services and products provider in Greater China. The Group principally offers tailor-made beauty and skin care solutions through its trained professional beauticians. The Group is engaged in research and development, manufacture and sale of skin care, aroma-therapeutic and beauty products, marketed under the brandname “NB®”. The products are distributed through a distribution network of over 1,300 NB’s SPAs and dedicated counters in Greater China.

Read More
Market

China Cord Blood Corporation Receives Notice of Transaction Regarding its 7% Senior Convertible Note Due 2017 Held by Golden Meditech

HONG KONG, Aug. 25, 2014 /PRNewswire/ — China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company has been informed that Magnum Opus International Holdings Limited (“Magnum”), a private vehicle that is controlled by CCBC Chairman Mr. Yuen KAM and involves the CCBC management team, together with Cordlife Group Limited (“Cordlife”), a Singapore listed company and substantial shareholder of the Company, have agreed to purchase the Company’s outstanding 7% senior convertible note due 2017 (the “Note”) held by Golden Meditech Holdings Limited (“Golden Meditech”), CCBC’s parent company, for a total consideration of approximately $88.1 million.

The Note was originally issued by the Company to Golden Meditech in 2012 with an aggregate principal amount of $50 million. Magnum and Cordlife are each obligated to purchase 50% of the Note, subject to customary closing conditions and satisfaction of all relevant approvals and consents, including but not limited to the approval of Golden Meditech’s independent shareholders.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services.  For more information, please visit our website at http://www.chinacordbloodcorp.com.        

About Magnum Opus International Holdings Limited

Magnum Opus International Holdings Limited is incorporated in the British Virgin Islands. It is controlled by Mr. Yuen KAM, CCBC’s chairman of the Board, and involves the CCBC management team. Mr. Yuen KAM is also the Chairman and Chief Executive Officer of Golden Meditech.

About Cordlife Group Limited (Bloomberg stock code: CLGL SP)

Incorporated in May 2001, Cordlife Group Limited is a multi-product healthcare company catering to the mother and child segment and a leading cord blood and umbilical cord lining banking services provider. Today, Cordlife operates the largest[1] private cord blood banks in each of Singapore, the Philippines and Indonesia, and is amongst the top three market leaders in Hong Kong and India. Cordlife also holds approximately 10.02% and 31.81% stakes in China Cord Blood Corporation and StemLife Berhad respectively, both of which are their countries’ largest cord blood bank operators. For more information, please visit www.cordlife.com.

[1] Source : Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com

ICR, Inc.
Mr. Bill Zima
Tel: (+86) 10-6583-7511 (China) or (+1) 646-405-5185 (U.S.)
Email: william.zima@icrinc.com

Read More
Market

Golden Meditech Announces the Disposal of Convertible Note Issued by CCBC for over US$88 million

HONG KONG, Aug. 25, 2014 /PRNewswire/ — Golden Meditech Holdings Limited (the “Company” or “Golden Meditech”, 801.HK; 910801.TW), a leading integrated healthcare enterprise in China, announced that it has entered into an agreement to sell its 7% senior convertible note due 2017 in an aggregate principal amount of US$50 million issued on 3 October 2012 by China Cord Blood Corporation (“CCBC”), a non-wholly-owned subsidiary of the Company (“Convertible Note”) to Magnum Opus International Holdings Limited (“Magnum”) and Cordlife Group Limited (“CGL”) for approximately US$88,090,000 (equivalent to approximately HK$682,697,500) in cash (the “Disposal”). Upon completion of the Disposal, each of Magnum and CGL will hold 50% of the Convertible Note.

Magnum is a private vehicle controlled by Mr. Kam Yuen, Chairman and Chief Executive Officer of the Company and Chairman of CCBC, and involves the CCBC management team. CGL is a cord blood banking services operator listed on the main board of the Singapore Exchange Securities Trading Limited, which currently owns approximately 10% of the issued shares of CCBC.

Following completion of the Disposal, Golden Meditech’s shareholding in CCBC will remain unchanged at approximately 42.0% and will only be diluted to approximately 33.9% if both Magnum and CGL exercise their rights to convert their Convertible Note into CCBC shares and, accordingly, their respective shareholdings in CCBC would increase by approximately 9.7%.

With mainland China’s healthcare sector continues to be driven by the government’s healthcare reform, Golden Meditech believes the Disposal would strengthen its financial position and liquidity, enhancing its ability to fund its potential acquisitions or expansion of its existing healthcare related businesses in mainland China.

The transaction is subject to Golden Meditech and CGL obtaining all relevant approvals and consents, including but not limited to the approval of Golden Meditech’s independent shareholders. An Extraordinary General Meeting (“EGM”) will be convened to consider and approve the transaction and a circular containing details of the Disposal and a notice of EGM are expected be dispatched to the shareholders no later than 16 September 2014.

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited (www.goldenmeditech.com) is China’s leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, including cord blood stem cells storage and hospital management, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China’s healthcare industry both through organic growth and strategic expansion.

Read More
Medical

ResMed Wins Initial Decision in ITC Patent Infringement Action

Judge Finds Nine BMC Products Infringe ResMed Patents

Judge Recommends Excluding U.S. Sale of BMC Masks and BMC Humidifier

SYDNEY and SAN DIEGO, Aug. 25, 2014 /PRNewswire/ — An administrative law judge at the International Trade Commission (ITC) ruled Friday August 22 in a patent infringement case brought by ResMed (NYSE: RMD) against Chinese medical device manufacturer BMC Medical Co., Ltd., that each of nine BMC products named in the action infringes one or more ResMed patents.  As a result, ITC Judge Thomas Pender recommended that the ITC ban BMC and its U.S. distributor, 3B Medical, from importing or selling any of the infringing BMC products in the United States.  Judge Pender also recommended a cease and desist order that would enjoin BMC and 3B from selling, advertising, marketing, storing or testing the infringing products in the United States.  ResMed is the innovation leader and pioneer in designing and manufacturing devices for the treatment of sleep-disordered breathing.

Judge Pender found that BMC’s InH2 humidifier, as well as original and redesigned versions of the following BMC masks infringe ResMed’s patents:

  • iVolve nasal mask
  • iVolve N2 nasal mask
  • Willow nasal pillows mask
  • iVolve full face mask

“The Judge’s decision is not just a victory for ResMed and the product innovation that is core to our brand, but it’s also a win for patients who deserve high quality, comfortable care,” said David Pendarvis, ResMed chief administrative officer and global general counsel. “We will continue innovating and continue protecting our intellectual property anywhere we identify infringement.”

About ResMed:
ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:

For News Media

For Investors

Gretchen Griswold

Agnes Lee

Director, Global Corporate Communications

Senior Director, Investor Relations

O: +1-858-836-6789

O: +1-858-836-5971

news@resmed.com

investorrelations@resmed.com

Logo – http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a

Read More